A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Critical Care

Volumn 13, Issue 2, 2009, Pages

  Laterre, Pierre François ^a   Opal, Steven M ^b   Abraham, Edward ^c   LaRosa, Steven P ^b   Creasey, Abla A ^d   Xie, Fang ^e   Poole, Lona ^e   Wunderink, Richard G ^f  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b RHODE ISLAND HOSPITAL   (United States)

^c University of Alabama at Birmingham   (United States)

^d ALZA CORPORATION   (United States)

^e NOVARTIS   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; PLACEBO; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; PROTEIN;

APACHE; ARTICLE; BLEEDING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECCHYMOSIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INJURY; INTOXICATION; MEDIASTINUM DISEASE; MORTALITY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT HEMORRHAGE; SEPSIS; SURVIVAL RATE; THORAX DISEASE; VASCULAR DISEASE; AGED; BACTERIAL PNEUMONIA; COMMUNICABLE DISEASE; FEMALE; GRAM NEGATIVE AEROBIC RODS AND COCCI; GRAM POSITIVE BACTERIUM; ISOLATION AND PURIFICATION; MALE; MICROBIOLOGY; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

AGED; APACHE; CLINICAL TRIALS, PHASE III AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GRAM-NEGATIVE AEROBIC BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 63149094677     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc7747     Document Type: Article

References (33)

1. Angus DC Linde-Zwirble WT Lidicker J Clermont G Carcillo J Pinsky MR Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care Crit Care Med 2001, 29:1303-1310. 10.1097/00003246-200107000-00002 11445675
2. Opal S Laterre PF Abraham E Francois B Wittebole X Lowry S Dhainaut JF Warren B Dugernier T Lopez A Sanchez M Demeyer I Jauregui L Lorente JA McGee W Reinhart K Kljucar S Souza S Pribble J Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators Recombinant human platelet-activating factor acetylhydrolase for the treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial Crit Care Med 2004, 32:332-341. 10.1097/01.CCM.0000108867.87890.6D 14758145
3. Warren BL Eid A Singer P Pillay SS Carl P Novak I Chalupa P Atherstone A Pénzens I Kübler A Knaub S Keinecke HO Heinrichs H Schindel F Juers M Bone RC Opal SM KyberSept Trial Study Group High-dose antithrombin III in severe sepsis (the KyberSept trial) JAMA 2001, 286:1869-1187. 10.1001/jama.286.15.1869 11597289
4. Bernard G Vincent JL Laterre PF LaRosa SP Dhainaut JF Lopez-Rodriguez A Steingrub JS Garber GE Helterbrand JD Ely EW Fisher CJ Jr Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001, 344:699-709. 10.1056/NEJM200103083441001 11236773
5. Annane D Sebille V Charpentier C Bollaert PE François B Korach JM Capellier G Cohen Y Azoulay E Troché G Chaumet-Riffaut P Bellissant E Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock JAMA 2002, 288:862-871. 10.1001/jama.288.7.862 12186604
6. Bartlett JG Dowell SF Mandell LA File TM Jr Musher DM Fine MJ Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America Clin Infect Dis 2000, 31:347-382. 10.1086/313954 10987697
7. Camerer E Kolsto AB Prydz H Cell biology of tissue factor, the principal initiator of blood coagulation Thromb Res 1996, 81:1-41. 10.1016/ 0049-3848(95)00209-X 8747518
8. Levi M Poll van der T ten Cate H Tissue factor in infection and severe inflammation Semin Thromb Hemost 2006, 32:33-39. 10.1055/s-2006-933338 16479460
9. Choi G Schultz MJ van Till JW Bresser P Zee van der JS Boermeester MA Levi M Poll van der T Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection Eur Respir J 2004, 24:786-789. 10.1183/09031936.04.00140703 15516673
10. Gando S Kameue T Matsuda N Hayakawa M Morimoto Y Ishitani T Kemmotsu O Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients Thromb Res 2003, 109:119-124. 10.1016/ S0049-3848(03)00151-8 12706640
11. Welty-Wolf KE Carraway MS Miller DL Ortel TL Ezban M Ghio AJ Idell S Piantadosi CA Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons Am J Respir Crit Care Med 2001, 164:1988-1996. 11734456
12. Miller DL Welty-Wolf K Carraway MS Ezban M Ghio A Suliman H Piantadosi CA Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide Am J Respir Cell Mol Biol 2002, 26:650-658. 12034563
13. Enkhbaatar P Okajima K Murakami K Uchiba M Okabe H Okabe K Yamaguchi Y Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation Am J Respir Crit Care Med 2000, 162:1752-1759. 11069808
14. Bajaj MS Birktoft JJ Steer SA Bajaj SP Structure and biology of tissue factor pathway inhibitor Thromb Haemost 2001, 86:959-972. 11686353
15. Abraham E Reinhart K Opal S Demeyer I Doig C Rodriguez AL Beale R Svoboda P Laterre PF Simon S Light B Spapen H Stone J Seibert A Peckelsen C De Deyne C Postier R Pettila V Artigas A Percell SR Shu V Zwingelstein C Tobias J Poole L Stolzenbach JC Creasey AA OPTIMIST Trial Study Group Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized controlled trial JAMA 2003, 290:238-247. 10.1001/jama.290.2.238 12851279
16. Sprung CL Finch RG Thijs LG Glauser MP International Sepsis Trial (INTERSEPT): Role and impact of a clinical evaluation Committee Crit Care Med 1996, 24:1441-1447. 10.1097/00003246-199609000-00003 8797613
17. Opal SM Fisher CJJ Dhainaut JF Vincent JL Brase R Lowry SF Sadoff JC Slotman GJ Levy H Balk RA Shelly MP Pribble JP LaBrecque JF Lookabaugh J Donovan H Dubin H Baughman R Norman J DeMaria E Matzel K Abraham E Seneff M Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Investigator Group Crit Care Med 1997, 25:1115-1124. 10.1097/00003246-199707000-00010 9233735
18. Dhainaut JF Laterre PF LaRosa SP Levy H Garber GE Heiselman D Kinasewitz GT Light RB Morris P Schein R Sollet JP Bates BM Utterback BG Maki D The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology, and results Crit Care Med 2003, 31:2291-2301. 10.1097/ 01.CCM.0000085089.88077.AF 14501959
19. Laterre PF Garber G Levy H Wunderink R Kinasewitz GT Sollet JP Maki DG Bates B Yan SC Dhainaut JF PROWESS Clinical Evaluation Committee Severe community-acquired pneumonia as a cause of severe sepsis: Data from the PROWESS study Crit Care Med 2005, 33:952-961. 10.1097/ 01.CCM.0000162381.24074.D7 15891319
20. Rosón B Carratalà J Fernández-Sabé N Tubau F Manresa F Gudiol F Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia Arch Intern Med 2004, 164:502-508. 10.1001/archinte.164.5.502 15006826
21. Menéndez R Torres A Zalacaín R Aspa J Martín Villasclaras JJ Borderías L Benítez Moya JM Ruiz-Manzano J Rodríguez de Castro F Blanquer J Pérez D Puzo C Sánchez Gascón F Gallardo J Alvarez C Molinos L Neumofail Group Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome Thorax 2004, 59:960-965. 1746855 15516472 10.1136/thx.2003.017756
22. Siegel JP Assessing the use of activated protein C in the treatment of severe sepsis N Engl J Med 2002, 347:1030-1034. 10.1056/NEJMsb021512 12324563
23. Christ-Crain M Jaccard-Stolz D Bingisser R Gencay MM Huber PR Tamm M Muller B Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: Cluster-randomised, single-blinded intervention trial Lancet 2004, 363:600-607. 10.1016/ S0140-6736(04)15591-8 14987884
24. Gross TJ Simon RH Sitrin RG Tissue factor procoagulant expression by rat alveolar epithelial cells Am J Respir Cell Mol Biol 1992, 6:397-403. 1550685
25. McGee MP Wallin R Wheeler FB Rothberger H Initiation of the extrinsic pathway of coagulation by human and rabbit alveolar macrophages: A kinetic study Blood 1989, 74:1583-1590. 2790188
26. Levi M Schultz MJ Rijneveld AW Poll van der T Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia Crit Care Med 2003, 31:S238-S242. 10.1097/01.CCM.0000057849.53689.65 12682446
27. Luyt CE Guerin V Combes A Trouillet JL Ayed SB Bernard M Gibert C Chastre J Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia Am J Respir Crit Care Med 2005, 171:48-53. 10.1164/rccm.200406-746OC 15447947
28. Opal SM Garber GE LaRosa SP Maki DG Freebairn RC Kinasewitz GT Dhainaut JF Yan SB Williams MD Graham DE Nelson DR Levy H Bernard GR Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated) Clin Infect Dis 2003, 37:50-58. 10.1086/375593 12830408
29. Park CT Creasey AA Wright SD Tissue factor pathway inhibitor blocks cellular effects of endotoxin by binding to endotoxin and interfering with transfer to CD14 Blood 1997, 89:4268-4274. 9192748
30. Opal SM Scannon PJ Vincent JL White M Carroll SF Palardy JE Parejo NA Pribble JP Lemke JH Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock J Infect Dis 1999, 180:1584-1589. 10.1086/315093 10515819
31. Hardy S Schirm S Liu X Dai Y Tifacogin increases bacterial clearance from blood Crit Care 2006, 10:P155. 10.1186/cc4502
32. Lupu C Poulsen E Roquefeuil S Westmuckett AD Kakkar VV Lupu F Cellular effects of heparin on the production and release of tissue factor pathway inhibitor in human endothelial cells in culture Arterioscler Thromb Vasc Biol 1999, 19:2251-2262. 10479670
33. Eichacker PQ Parent C Kalil A Esposito C Cui X Banks SM Gertenberger EP Fitz Y Danner RL Natanson C Risk and efficacy of anti-inflammatory agents: Retrospective and confirmatory studies of sepsis Am J Respir Crit Care Med 2002, 166:1197-1205. 10.1164/rccm.200204-302OC 12403688